1969309-56-5
1969309-56-5 structure
- Name: Zenocutuzumab
- Chemical Name: Zenocutuzumab
- CAS Number: 1969309-56-5
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways JAK/STAT Signaling EGFR
- Create Date: 2023-01-14 21:00:20
- Modify Date: 2024-01-04 19:20:16
-
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3[1].
| Name | Zenocutuzumab |
|---|
| Description | Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Zenocutuzumab（0.001-1000 nM；96 小时）抑制肺癌和乳腺癌细胞系的细胞生长[1]。 Zenocutuzumab（0.1-1000 nM；24 小时）抑制 HER3 和 AKT 磷酸化，在肺癌和乳腺癌细胞系中诱导细胞凋亡和细胞周期停滞的标志物[1]。 Cell Viability Assay[1] Cell Line: Human bronchiolar epithelial cell lines (HBEC) Concentration: 0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM Incubation Time: 96 h Result: Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions. Western Blot Analysis[1] Cell Line: HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells Concentration: 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM Incubation Time: 24 hours Result: Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation. |
| In Vivo | Zenocutuzumab（2.5-25 mg/kg；腹腔注射；每周一次；持续 28 天）导致生长显着减少，包括肿瘤消退[1]。 Animal Model: 6 to 12-week-old female NSG™ (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors[1]. Dosage: 2.5 mg/kg, 8 mg/kg, or 25 mg/kg Administration: i.p.; once weekly; for 28 days Result: Blocked growth of lung and ovarian cancer PDX models. |
| References |
| No Any Chemical & Physical Properties |